Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

163 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy.
van Duin M, Broyl A, de Knegt Y, Goldschmidt H, Richardson PG, Hop WC, van der Holt B, Joseph-Pietras D, Mulligan G, Neuwirth R, Sahota SS, Sonneveld P. van Duin M, et al. Among authors: neuwirth r. Haematologica. 2011 Nov;96(11):1662-9. doi: 10.3324/haematol.2010.037978. Epub 2011 Jul 26. Haematologica. 2011. PMID: 21791470 Free PMC article. Clinical Trial.
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.
Vogl DT, Stadtmauer EA, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Facon T, Harousseau JL, Boral A, Neuwirth R, Anderson KC. Vogl DT, et al. Among authors: neuwirth r. Br J Haematol. 2009 Nov;147(4):531-4. doi: 10.1111/j.1365-2141.2009.07875.x. Epub 2009 Sep 1. Br J Haematol. 2009. PMID: 19725827 Free article. Clinical Trial.
Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma.
Ailawadhi S, Miecznikowski J, Gaile DP, Wang D, Sher T, Mulligan G, Bryant B, Wilding GE, Mashtare T, Stein L, Masood A, Neuwirth R, Lee KP, Chanan-Khan A. Ailawadhi S, et al. Among authors: neuwirth r. Leuk Lymphoma. 2012 Jun;53(6):1174-82. doi: 10.3109/10428194.2011.637212. Epub 2011 Dec 6. Leuk Lymphoma. 2012. PMID: 22054286
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.
San-Miguel JF, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Bladé J, Boccadoro M, Cavenagh JD, Neuwirth R, Boral AL, Esseltine DL, Anderson KC. San-Miguel JF, et al. Among authors: neuwirth r. Leukemia. 2008 Apr;22(4):842-9. doi: 10.1038/sj.leu.2405087. Epub 2008 Jan 17. Leukemia. 2008. PMID: 18200040 Clinical Trial.
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.
Chanan-Khan A, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Neuwirth R, Anderson KC, Richardson PG. Chanan-Khan A, et al. Among authors: neuwirth r. J Clin Oncol. 2008 Oct 10;26(29):4784-90. doi: 10.1200/JCO.2007.14.9641. Epub 2008 Aug 18. J Clin Oncol. 2008. PMID: 18711175 Clinical Trial.
Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.
Mulligan G, Lichter DI, Di Bacco A, Blakemore SJ, Berger A, Koenig E, Bernard H, Trepicchio W, Li B, Neuwirth R, Chattopadhyay N, Bolen JB, Dorner AJ, van de Velde H, Ricci D, Jagannath S, Berenson JR, Richardson PG, Stadtmauer EA, Orlowski RZ, Lonial S, Anderson KC, Sonneveld P, San Miguel JF, Esseltine DL, Schu M. Mulligan G, et al. Among authors: neuwirth r. Blood. 2014 Jan 30;123(5):632-9. doi: 10.1182/blood-2013-05-504340. Epub 2013 Dec 11. Blood. 2014. PMID: 24335104 Free PMC article. Clinical Trial.
TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia.
Ghobrial IM, Siegel DS, Vij R, Berdeja JG, Richardson PG, Neuwirth R, Patel CG, Zohren F, Wolf JL. Ghobrial IM, et al. Among authors: neuwirth r. Am J Hematol. 2016 Jun;91(4):400-5. doi: 10.1002/ajh.24300. Am J Hematol. 2016. PMID: 26800393 Free article. Clinical Trial.
Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution.
Tang M, Zhao R, van de Velde H, Tross JG, Mitsiades C, Viselli S, Neuwirth R, Esseltine DL, Anderson K, Ghobrial IM, San Miguel JF, Richardson PG, Tomasson MH, Michor F. Tang M, et al. Among authors: neuwirth r. Clin Cancer Res. 2016 Aug 15;22(16):4206-4214. doi: 10.1158/1078-0432.CCR-15-2793. Epub 2016 Mar 22. Clin Cancer Res. 2016. PMID: 27006493 Free PMC article.
163 results